Johannes Ott

Jun 13, 2024 | tandfonline.com | Marlene Hager |Victoria Fitz |Johannes Ott |Tal Goldstein

ABSTRACTIntroduction In many postmenopausal women, quality of life is decreased due to vasomotor symptoms. Efficient and well-tolerated non-hormonal treatment options are needed. Areas covered The present review summarizes what is known about the etiology of postmenopausal vasomotor symptoms as a rationale for the mechanism of action of Elinzanetant, a new neurokinin (NK)-1/-3 receptor antagonist, as well as its efficacy and side effect profile.